Targeting STAT3 affects melanoma on multiple fronts
- 1 June 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer and Metastasis Reviews
- Vol. 24 (2), 315-327
- https://doi.org/10.1007/s10555-005-1580-1
Abstract
As a point of convergence for numerous oncogenic signaling pathways, STAT3 is constitutively-activated at 50 to 90% frequency in diverse human cancers, including melanoma. A critical role of STAT3 in tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion has been recently demonstrated. STAT3 contributes to tumor cell growth by regulating the expression of genes that are involved in cell survival and proliferation. STAT3 promotes metastasis and angiogenesis by inducing expression of the metastatic gene, MMP-2, and the potent angiogenic gene, VEGF. STAT3 participates in the regulation of tumor immune evasion by inhibiting expression of proinflammatory mediators while promoting expression of immune-suppressing factors, which in turn activates STAT3 signaling in dendritic cells leading to immune tolerance. Thus, targeting STAT3 for therapy assaults cancer on multiple fronts. Many of the studies that defined STAT3’s role in oncogenesis were carried out in melanoma cells and tumor models. In this review, we summarize the key role of STAT3 in cancer in general and melanoma in particular. With the emergence of small-molecule drugs that directly inhibit STAT3 or the oncogenic signaling pathways upstream of STAT3 in melanoma, a promising novel approach for melanoma therapy is emerging.Keywords
This publication has 121 references indexed in Scilit:
- Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasisOncogene, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- The genetics of malignant melanoma: lessons from mouse and manNature Reviews Cancer, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002
- Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesisOncogene, 2002
- STATs in oncogenesisOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990